ClinicalTrials.gg
CompletedNCT05038982Updated Jul 3, 2023Results posted

Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

A Phase 2 interventional study of Abrocitinib in Prurigo Nodularis, Pruritus and Chronic Pruritus, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.

Enrollment
127th of 153
20 · median 70
Started
2021
with 7 others
Phase 2
60 of 163
6 open now
Registered
111th of 163
by date
Lead sponsor
5 of 163
Johns Hopkins University

Among the 163 studies in Pruritus with a site in United States, this one is the 127th largest by enrollment of the 153 interventional ones that give a count, is one of 8 that started in 2021, is one of 60 in phase 2, and was the 111th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies in Pruritus with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.

Read the detailed description

This is a trial to assess the efficacy of Abrocitinib as a therapeutic for Prurigo Nodularis (PN) and Chronic Pruritus of Unknown Origin (CPUO). The study will consist of a 4-week Screening period, a 12-week treatment period and then a 4-week follow up period. The arms will run in parallel and patients will take 200 mg oral Abrocitinib daily for the duration of the 12-week treatment period.

03

Conditions studied

  • Prurigo Nodularis
  • Pruritus
  • Chronic Pruritus
  • Chronic Prurigo
  • Skin Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or female participants between ages 18-80 years at time of signing
  • A clinical diagnosis of prurigo nodularis, defined by the presence of at least 10 pruritic nodules on at least 2 different anatomic locations (with each arm, leg, and anterior and posterior trunk considered distinct anatomic locations)

OR

  • Subject has ongoing chronic pruritus of unknown origin, which must be present on multiple segments on the body. CPUO patients must not have known dermatologic or systemic conditions, that in the opinion of the investigator, are the cause of patient's pruritus
  • Subject has moderate to severe pruritus, defined as average peak pruritus numeric rating scale - (PP-NRS) > 7 (range 0-10, higher score indicating greater degree of pruritus severity) in the 7 days prior to the Screening Visit.
  • Female participants are eligible for the study if they are not pregnant, planning to become pregnant or breastfeeding during the study or not a woman of child bearing potential ()

Exclusion criteria

Exclusion Criteria:

  • Infected with or viruses.
  • Infected with Herpes Simplex or Herpes zoster.
  • Positive serology at screening,
  • Evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
  • History of lymphoproliferative disease, or active primary or recurrent
  • History of recurrent (≥ 2) venous thromboembolism (VTE) or (DVT/PE) - deep vein thrombosis and pulmonary embolism
  • Untreated thyroid, adrenal, or pituitary disease or nodules, or history of thyroid malignancy
  • Have received any of the following treatment regiments specified in the timeframes outlined below:

    • Within 6 months of first dose of study drug: Rituximab, any other B cell depleting therapies, or intravenous immunoglobulin (IVIg)
    • Within 12 weeks of first dose of study drug: Any studies with Janus kinase (JAK) inhibitors; Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab (or another anti-interferon (IFN) therapy)
    • Within 8 weeks of first dose of study drug: Other biologics
    • Within 6 weeks: Have been vaccinated with live or attenuated .
    • Within 4 weeks: Participation in other studies involving drug(s)
    • Within 4 weeks: Use of oral immune suppressants; systemic therapies, neuromodulatory therapies, Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.
    • Within 1 week of first dose of study drug: Topical treatments that could affect PN; Herbal medications with unknown properties or known beneficial effects for PN.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Prurigo Nodularis

    Prurigo Nodularis (PN) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).

    Drug: Abrocitinib

  • Experimental
    Chronic Pruritus of Unknown Origin

    Chronic Pruritus of Unknown Origin (CPUO) patients only: Study Design: Subjects meeting study criteria will undergo a 4-week washout period of other therapies that could impact pruritus through the end of the study (including antihistamines, topical steroids, systemic antipruritic therapies or immunosuppressants).

    Drug: Abrocitinib

Interventions

  • During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.

06

What researchers measure

Primary outcomes

  1. Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12

    Percent change in weekly average PP-NRS at Week 12. PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Number of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 12

    Number of subjects achieving at least a 4-point reduction from baseline in weekly average PP-NRS at Week 12. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

    Time frame: Up to 12 weeks

  2. Itch Severity Assessed by 5-D Pruritus Scale at Baseline and Week 12

    Assess itch severity as assessed by 5-D pruritus scale. The 5-D pruritus scale scores pruritus over the past 2 weeks along 5 dimensions: duration, degree, direction, disability and distribution. Duration, degree and direction are scored from 1 to 5, with "1" indicating better control and resolution of symptoms, and "5" indicating increased intensity, severity and worsening. Disability is assessed in Leisure/Social, housework/errands, and work/school with scores ranging from N/A, and 1-5, with "1" indicating that itch never affects the activity, and "5" meaning that itch always affects this activity. The scores of each of the 5 domains are achieved separately and then summed together to obtain a total score. Scores can range between 5 no pruritus, and 25 most severe pruritus.

    Time frame: Baseline (week 0) and 12 weeks

  3. Quality of Life as Assessed by the Dermatology Quality of Life Index From Baseline and Week 12

    Quality of life as assessed by the Dermatology Quality of Life Index (DLQI). The DLQI is 10 questions used to assess impact of skin disease. Scores range from 0-30, with "0" corresponding to best quality of life, and "30" corresponding to worst quality of life.

    Time frame: Baseline (week 0) and 12 weeks

  4. Pruriginous Lesions as Assessed by the Prurigo Activity Score From Baseline and Week 12

    Pruriginous lesions as assessed by the Prurigo Activity Score (PAS). The PAS is a 7-item questionnaire that assesses the number, distribution and activity of pruriginous lesions. The score is calculated via summation of the scoring values, added up with 123 and afterwards divided by 10. This results in a range of values from 1.3 to 21.3.

    Time frame: Baseline (week 0) and 12 weeks

  5. Itch-scratching Behavior as Assessed by Patient Reported Outcomes Measurement Information System at Baseline and Week 12

    Itch-scratching behavior as assessed by Patient Reported Outcomes Measurement Information System (PROMIS®) Itch Questionnaire (PIQ) T-Score: Scratching. The PIQ T-Score: Scratching, is comprised of 5 questions to assess Itch-Scratching Behavior over the past 7 days. Scores for each question range from 1-5, Score range of 5-25 with scores of "1" indicating less scratching behavior and scores of "5" indicating the greatest scratching behavior. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Itch, a T-score of 60 is one SD worse than average. By comparison, an Itch T-score of 40 is one SD better than average For PROMIS, the T-scores have a mean (SD) of 50 (10) for adults in the US experiencing itch for any reason.

    Time frame: Baseline (week 0) and 12 weeks

  6. Number of Nodules at Baseline and Week 12

    Number of baseline prurigo nodules over time. As part of the Prurigo Activity Score, lesions are counted in a representative body region. Lesion count within the representative area at Week 0 was compared to lesion count in the representative area at Week 12.

    Time frame: Baseline (week 0) and 12 weeks

  7. Prurigo Nodule Severity at Baseline and Week 12

    Prurigo nodule severity using the Investigator's Global Assessment (IGA). The IGA is a physician scale assessing the number of nodules a Prurigo Nodularis (PN) patient has. Patients receive a score between 0 and 4, where "0" is clear: "No prurigo nodules. Post-inflammatory hypo/hyper pigmentation may be present". Grades of "4" are severe: "Abundant prurigo nodules. Marked nodule elevation."

    Time frame: Baseline (week 0) and 12 weeks

  8. Quality of Life as Assessed by the EuroQoL 5-Dimension at Baseline and Week 12

    Quality of life as assessed by EuroQoL 5-Dimension (EQ-5D). The 3 level version of the EQ-5D (EQ-5D-3L) assesses degree of debilitation in 5 major aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three possible answers. These answers equate to: "No problems" or "Some/Moderate Problems" or "Severe/Extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. A unique health state is then defined by combining one level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code. A total of 243 possible health states codes is defined in this way. State 11111 indicates no problems on any of the five dimensions. The patient then rates how good or bad their health is on that day from a range from 0 the worst health you can imagine, to 100 the best health you can imagine.

    Time frame: Baseline (week 0) and 12 weeks

  9. Depression as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12

    Depression as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to depression. Each item scored from 0-3 with higher scores indicating higher depression. Total score range 0-21.

    Time frame: Baseline (week 0) and 12 weeks

  10. Anxiety as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12

    Anxiety as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to anxiety. Each item scored from 0-3 with higher scores indicating higher anxiety. Total score range 0-21.

    Time frame: Baseline (week 0) and 12 weeks

  11. Sleep Disturbance as Assessed by the SD-NRS at Baseline and Week 12

    Average sleep disturbance from Week 0 and Week 12 as assessed by (SD) NRS. The SD-NRS is an 11-point scale (0 -10) with higher scores indicating greater sleep disturbance.

    Time frame: Baseline (week 0) and 12 weeks

  12. Itch Intensity in Patients With Underlying Atopy at Baseline and Week 12

    Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients with underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.

    Time frame: Baseline (week 0) and 12 weeks

  13. Itch Intensity in Patients Without Underlying Atopy at Baseline and Week 12

    Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients without underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy is defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.

    Time frame: Baseline (week 0) and 12 weeks

  14. Itch Intensity in CPUO Patients With High Eosinophilia at Baseline and Week 12

    Itch intensity as measured by PP-NRS in CPUO patients with high eosinophilia (greater than 500 eosinophils per micro-liter of blood). The PP-NRS is an 11-point single self-report item on a scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

    Time frame: Baseline (week 0) and 12 weeks

  15. Cutaneous Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12

    Lesional and non-lesional skin biopsies will be compared for Type 1/2/17/22 T Helper (Th) Th1/Th2/Th17/Th22 polarization before and after treatment. PN and CPUO patients had biopsies collected at Week 0 and at Week 12. PN patients had two biopsies collected: a lesional site and a non-lesional biopsy close by for comparison. The CPUO patients only had one biopsy collected at the timepoints because there are no visible lesions. CPUO will be compared from week 0 to week 12. PN will compare Lesional to non Lesional at Week 0. PN will compare Lesional to Non Lesional at Week 12. GSVA will compare gene set enrichment scores as a function of gene pathway expression which range from -1 to 1. Lower scores indicate down regulation of the gene set, and higher scores indicate up regulation.

    Time frame: Baseline (week 0) and 12 weeks

  16. Systemic Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12

    Plasma cytokines will be analyzed for TH1/Th2/Th17/Th22 polarization before and after treatment. This outcome was posted in error. It is not appropriate to perform GSVA of plasma cytokines. It is best practice to limit GSVA to RNASeq.

    Time frame: Baseline and 12 weeks

07

Results

Posted Jul 3, 2023

Participant flow

Patients were recruited by referral or at Johns Hopkins Dermatology clinic between September 2021 and March 2022

Participant flow — Overall Study
MilestonePrurigo NodularisChronic Pruritus of Unknown Origin
Started1010
End of intervention period. week 12: per protocol population1010
Follow-up period (4 weeks)108
Completed108
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryPercent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12

Percent change in weekly average PP-NRS at Week 12. PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

Time frame:
Up to 12 weeks
Reported as:
Mean · percent change
Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12
percent changePrurigo NodularisChronic Pruritus of Unknown Origin
Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12-78.26 (-118.48 to -38.09)-53.66 (-98.76 to -8.55)
Statistical analysis
  • Prurigo Nodularis · ANOVA · p = <0.001 (Threshold of significance at 0.05.) · Mean difference (net): 78.26 · 95% CI 38.09 to 118.48Percent PP-NRS reduction comparing subject's values at Week 0 to values at Week 12
  • Chronic Pruritus of Unknown Origin · ANOVA · p = 0.0142 (Threshold of significance at 0.05.) · Mean difference (net): 53.66 · 95% CI 8.55 to 98.76Percent PP-NRS reduction comparing subject's values at Week 0 to values at Week 12
SecondaryNumber of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 12

Number of subjects achieving at least a 4-point reduction from baseline in weekly average PP-NRS at Week 12. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 12
ParticipantsPrurigo NodularisChronic Pruritus of Unknown Origin
Number of Subjects Achieving a Reduction in Weekly Average PP-NRS From Baseline to Week 1286
SecondaryItch Severity Assessed by 5-D Pruritus Scale at Baseline and Week 12

Assess itch severity as assessed by 5-D pruritus scale. The 5-D pruritus scale scores pruritus over the past 2 weeks along 5 dimensions: duration, degree, direction, disability and distribution. Duration, degree and direction are scored from 1 to 5, with "1" indicating better control and resolution of symptoms, and "5" indicating increased intensity, severity and worsening. Disability is assessed in Leisure/Social, housework/errands, and work/school with scores ranging from N/A, and 1-5, with "1" indicating that itch never affects the activity, and "5" meaning that itch always affects this activity. The scores of each of the 5 domains are achieved separately and then summed together to obtain a total score. Scores can range between 5 no pruritus, and 25 most severe pruritus.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Itch Severity Assessed by 5-D Pruritus Scale at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 018.60 (14.98 to 22.22)17.40 (14.89 to 19.91)
Week 129.20 (7.59 to 10.81)11.30 (6.40 to 16.20)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.002 (Threshold of significance at 0.05.) · Mean difference (net): 9.40 · 95% CI 6.3 to 12.5
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.0215 (Threshold of significance at 0.05.) · Mean difference (net): 6.10 · 95% CI 1.6 to 10.6
SecondaryQuality of Life as Assessed by the Dermatology Quality of Life Index From Baseline and Week 12

Quality of life as assessed by the Dermatology Quality of Life Index (DLQI). The DLQI is 10 questions used to assess impact of skin disease. Scores range from 0-30, with "0" corresponding to best quality of life, and "30" corresponding to worst quality of life.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Quality of Life as Assessed by the Dermatology Quality of Life Index From Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 019.0 (13.30 to 24.70)9.60 (6.40 to 12.80)
Week 128.90 (4.31 to 13.49)4.90 (2.68 to 7.12)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.002 (Threshold of significance at 0.05.) · Mean difference (net): 10.1 · 95% CI 5.9 to 14.3
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.02 (Threshold of significance at 0.05.) · Mean difference (net): 4.7 · 95% CI 0.77 to 8.6
SecondaryPruriginous Lesions as Assessed by the Prurigo Activity Score From Baseline and Week 12

Pruriginous lesions as assessed by the Prurigo Activity Score (PAS). The PAS is a 7-item questionnaire that assesses the number, distribution and activity of pruriginous lesions. The score is calculated via summation of the scoring values, added up with 123 and afterwards divided by 10. This results in a range of values from 1.3 to 21.3.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Pruriginous Lesions as Assessed by the Prurigo Activity Score From Baseline and Week 12
score on a scalePrurigo Nodularis
Week 014.76 (13.04 to 16.48)
Week 129.32 (6.57 to 12.07)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0078 (Threshold of significance at 0.05.) · Mean difference (net): 5.44 · 95% CI 2.70 to 8.18
SecondaryItch-scratching Behavior as Assessed by Patient Reported Outcomes Measurement Information System at Baseline and Week 12

Itch-scratching behavior as assessed by Patient Reported Outcomes Measurement Information System (PROMIS®) Itch Questionnaire (PIQ) T-Score: Scratching. The PIQ T-Score: Scratching, is comprised of 5 questions to assess Itch-Scratching Behavior over the past 7 days. Scores for each question range from 1-5, Score range of 5-25 with scores of "1" indicating less scratching behavior and scores of "5" indicating the greatest scratching behavior. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Itch, a T-score of 60 is one SD worse than average. By comparison, an Itch T-score of 40 is one SD better than average For PROMIS, the T-scores have a mean (SD) of 50 (10) for adults in the US experiencing itch for any reason.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · T-score
Itch-scratching Behavior as Assessed by Patient Reported Outcomes Measurement Information System at Baseline and Week 12
T-scorePrurigo NodularisChronic Pruritus of Unknown Origin
Week 053.76 (48.74 to 58.78)45.60 (41.57 to 49.63)
Week 1241.03 (32.67 to 49.39)35.72 (30.28 to 41.16)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0098 (Threshold of significance at 0.05.) · Mean difference (net): 12.73 · 95% CI 5.57 to 19.89
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.0117 (Threshold of significance at 0.05.) · Mean difference (net): 9.88 · 95% CI 3.10 to 16.66
SecondaryNumber of Nodules at Baseline and Week 12

Number of baseline prurigo nodules over time. As part of the Prurigo Activity Score, lesions are counted in a representative body region. Lesion count within the representative area at Week 0 was compared to lesion count in the representative area at Week 12.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · Lesion count
Number of Nodules at Baseline and Week 12
Lesion countPrurigo Nodularis
Week 014.90 (9.21 to 20.59)
Week 124.70 (2.59 to 6.81)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.002 (Threshold of significance at 0.05.) · Mean difference (net): 10.20 · 95% CI 4.46 to 15.94
SecondaryPrurigo Nodule Severity at Baseline and Week 12

Prurigo nodule severity using the Investigator's Global Assessment (IGA). The IGA is a physician scale assessing the number of nodules a Prurigo Nodularis (PN) patient has. Patients receive a score between 0 and 4, where "0" is clear: "No prurigo nodules. Post-inflammatory hypo/hyper pigmentation may be present". Grades of "4" are severe: "Abundant prurigo nodules. Marked nodule elevation."

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Prurigo Nodule Severity at Baseline and Week 12
score on a scalePrurigo Nodularis
Week 03.60 (3.23 to 3.97)
Week 122.50 (1.99 to 3.01)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0078 (Threshold of significance at 0.05.) · Mean difference (net): 1.10 · 95% CI 0.57 to 1.63
SecondaryQuality of Life as Assessed by the EuroQoL 5-Dimension at Baseline and Week 12

Quality of life as assessed by EuroQoL 5-Dimension (EQ-5D). The 3 level version of the EQ-5D (EQ-5D-3L) assesses degree of debilitation in 5 major aspects of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three possible answers. These answers equate to: "No problems" or "Some/Moderate Problems" or "Severe/Extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. A unique health state is then defined by combining one level from each of the 5 dimensions. Each state is referred to in terms of a 5-digit code. A total of 243 possible health states codes is defined in this way. State 11111 indicates no problems on any of the five dimensions. The patient then rates how good or bad their health is on that day from a range from 0 the worst health you can imagine, to 100 the best health you can imagine.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Quality of Life as Assessed by the EuroQoL 5-Dimension at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 00.60 (0.33 to 0.87)0.74 (0.55 to 0.93)
Week 120.75 (0.52 to 0.99)0.86 (0.67 to 1.05)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0391 (Threshold of significance at 0.05.) · Mean difference (net): 0.15 · 95% CI 0.025 to 0.27
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.28 (Threshold of significance at 0.05.) · Mean difference (net): 0.12 · 95% CI -.080 to 0.31
SecondaryDepression as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12

Depression as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to depression. Each item scored from 0-3 with higher scores indicating higher depression. Total score range 0-21.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Depression as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 06.90 (3.42 to 10.38)4.20 (0.93 to 7.47)
Week 123.30 (0.398 to 6.202)3.10 (0.310 to 5.890)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0684 (Threshold of significance at 0.05.) · Mean difference (net): 3.6 · 95% CI 0.035 to 7.235
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.375 (Threshold of significance at 0.05.) · Mean difference (net): 1.10 · 95% CI -3.656 to 1.456
SecondaryAnxiety as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12

Anxiety as assessed by The Hospital Anxiety and Depression Scale (HADS), has 7 items relating to anxiety. Each item scored from 0-3 with higher scores indicating higher anxiety. Total score range 0-21.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Anxiety as Assessed by The Hospital Anxiety and Depression Scale at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 06.60 (2.62 to 10.58)4.30 (0.061 to 8.54)
Week 125.90 (2.61 to 9.20)4.30 (0.27 to 8.33)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.207 (Threshold of significance at 0.05.) · Mean difference (net): 0.70 · 95% CI -3.44 to 2.04
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.8125 (Threshold of significance at 0.05.) · Mean difference (net): 0 · 95% CI -3.389 to 3.389
SecondarySleep Disturbance as Assessed by the SD-NRS at Baseline and Week 12

Average sleep disturbance from Week 0 and Week 12 as assessed by (SD) NRS. The SD-NRS is an 11-point scale (0 -10) with higher scores indicating greater sleep disturbance.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Sleep Disturbance as Assessed by the SD-NRS at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Week 07.20 (5.52 to 8.88)5.10 (2.66 to 7.54)
Week 122.40 (-0.060 to 4.86)2.80 (-0.017 to 5.62)
Statistical analysis
  • Prurigo Nodularis · Wilcoxon matched pairs signed rank test · p = 0.0039 (Threshold of significance at 0.05.) · Mean difference (net): 4.80 · 95% CI 2.52 to 7.08
  • Chronic Pruritus of Unknown Origin · Wilcoxon matched pairs signed rank test · p = 0.0547 (Threshold of significance at 0.05.) · Mean difference (net): 2.3 · 95% CI -0.0376 to 4.638
SecondaryItch Intensity in Patients With Underlying Atopy at Baseline and Week 12

Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients with underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Itch Intensity in Patients With Underlying Atopy at Baseline and Week 12
score on a scalePrurigo Nodularis
Week 09.67 (8.23 to 11.10)
Week 120.67 (-2.20 to 3.54)
Statistical analysis
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0003 (Threshold of significance at 0.05.) · Mean difference (net): 9.00 · 95% CI 6.93 to 11.07
SecondaryItch Intensity in Patients Without Underlying Atopy at Baseline and Week 12

Itch intensity as assessed by PP-NRS in Prurigo Nodularis patients without underlying atopy. The PP-NRS is a single self-report item on an 11-point scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable. Atopy is defined as a binary variable where patients have 2 out of 3: underlying history of atopic dermatitis, history of seasonal allergies, or asthma.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Itch Intensity in Patients Without Underlying Atopy at Baseline and Week 12
score on a scalePrurigo Nodularis
Week 09.00 (7.93 to 10.07)
Week 122.57 (0.075 to 5.07)
Statistical analysis
  • Prurigo Nodularis · t-test, 2 sided · p = <0.0001 (Threshold of significance at 0.05.) · Mean difference (net): 6.429 · 95% CI 4.011 to 8.846
SecondaryItch Intensity in CPUO Patients With High Eosinophilia at Baseline and Week 12

Itch intensity as measured by PP-NRS in CPUO patients with high eosinophilia (greater than 500 eosinophils per micro-liter of blood). The PP-NRS is an 11-point single self-report item on a scale (0 to10) where 0 is No itch, and 10 is the Worst itch imaginable.

Time frame:
Baseline (week 0) and 12 weeks

No measurements were reported for this outcome.

SecondaryCutaneous Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12

Lesional and non-lesional skin biopsies will be compared for Type 1/2/17/22 T Helper (Th) Th1/Th2/Th17/Th22 polarization before and after treatment. PN and CPUO patients had biopsies collected at Week 0 and at Week 12. PN patients had two biopsies collected: a lesional site and a non-lesional biopsy close by for comparison. The CPUO patients only had one biopsy collected at the timepoints because there are no visible lesions. CPUO will be compared from week 0 to week 12. PN will compare Lesional to non Lesional at Week 0. PN will compare Lesional to Non Lesional at Week 12. GSVA will compare gene set enrichment scores as a function of gene pathway expression which range from -1 to 1. Lower scores indicate down regulation of the gene set, and higher scores indicate up regulation.

Time frame:
Baseline (week 0) and 12 weeks
Reported as:
Mean · score on a scale
Cutaneous Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12
score on a scalePrurigo NodularisChronic Pruritus of Unknown Origin
Th1 Lesional Week 00.35 (0.0035 to 0.69)0.27 (0.076 to 0.46)
Th1 Non Lesional Week 0-0.085 (-0.31 to 0.14)—
Th1 Lesional Week 120.045 (-0.31 to 0.40)-0.31 (-0.49 to -0.14)
Th1 Non Lesional Week 12-0.36 (-0.70 to -0.021)—
Th2 Lesional Week 00.22 (-0.047 to 0.49)0.17 (0.016 to 0.32)
Th2 Non Lesional Week 0-0.11 (-0.31 to 0.086)—
Th2 Lesional Week 120.10 (-0.16 to 0.37)-0.20 (-0.32 to -0.083)
Th2 Non Lesional Week 12-0.18 (-0.44 to 0.080)—
Th17 Lesional Week 00.29 (0.048 to 0.52)0.12 (-0.10 to 0.33)
Th17 Non Lesional Week 0-0.29 (-0.52 to -0.062)—
Th17 Lesional Week 120.20 (-0.16 to 0.57)-0.099 (-0.25 to 0.050)
Th17 Non Lesional Week 12-0.083 (-0.45 to 0.29)—
Th22 Lesional Week 00.23 (-0.060 to 0.52)0.23 (0.048 to 0.42)
Th22 Non Lesional Week 0-0.29 (-0.50 to -0.071)—
Th22 Lesional Week 120.25 (-0.060 to 0.55)-0.15 (-0.34 to 0.034)
Th22 Non Lesional Week 12-0.16 (-0.49 to 0.17)—
Statistical analysis
  • Chronic Pruritus of Unknown Origin · t-test, 2 sided · p = <0.0001 (Threshold of significance set at 0.05) · Median difference (net): -0.58 · 95% CI -0.83 to -0.33
  • Chronic Pruritus of Unknown Origin · t-test, 2 sided · p = 0.0003 (The threshold for significance is set at 0.05) · Mean difference (net): -0.37 · 95% CI -0.56 to -0.18
  • Chronic Pruritus of Unknown Origin · t-test, 2 sided · p = 0.0952 (The threshold for significance is set at 0.05) · Mean difference (net): -0.21 · 95% CI -0.47 to 0.039
  • Chronic Pruritus of Unknown Origin · t-test, 2 sided · p = 0.004 (Threshold for significance is set at 0.05) · Mean difference (net): -0.38 · 95% CI -0.64 to -0.13
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0277 (The threshold of significance is set at 0.05) · Mean difference (net): -0.43 · 95% CI -0.81 to -0.053
  • Prurigo Nodularis · t-test, 2 sided · p = 0.077 (The threshold of significance is set at 0.05) · Mean difference (net): -0.40 · 95% CI -0.85 to 0.049
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0363 (The threshold of significance is set at 0.05) · Mean difference (net): -0.33 · 95% CI -0.64 to -0.024
  • Prurigo Nodularis · t-test, 2 sided · p = 0.10 (The threshold of significance is set at 0.05) · Mean difference (net): -0.29 · 95% CI -0.63 to 0.062
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0009 (The threshold for significance is set at 0.05) · Mean difference (net): -0.58 · 95% CI -0.89 to -0.27
  • Prurigo Nodularis · t-test, 2 sided · p = 0.2326 (The threshold for significance is set at 0.05) · Mean difference (net): -0.28 · 95% CI -0.77 to 0.20
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0047 (The threshold for significance is set at 0.05) · Mean difference (net): -0.52 · 95% CI -0.85 to -0.18
  • Prurigo Nodularis · t-test, 2 sided · p = 0.0539 (The threshold for significance is set at 0.05) · Mean difference (net): -0.41 · 95% CI -0.83 to 0.0076
SecondarySystemic Biomarker Analysis - Gene Set Variation Analysis (GSVA), at Baseline and Week 12

Plasma cytokines will be analyzed for TH1/Th2/Th17/Th22 polarization before and after treatment. This outcome was posted in error. It is not appropriate to perform GSVA of plasma cytokines. It is best practice to limit GSVA to RNASeq.

Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

Adverse events

Collected over From the first date of abrocitinib administration to the last date of abrocitinib administration + 4 week follow up, up to 16 weeks total.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prurigo Nodularis0/10 (0%)0/10 (0%)4/10 (40%)
Chronic Pruritus of Unknown Origin0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventPrurigo NodularisChronic Pruritus of Unknown Origin
HeadacheNervous system disorders1/100/10
NauseaGastrointestinal disorders1/100/10
FolliculitisSkin and subcutaneous tissue disorders0/101/10
Acneiform EruptionSkin and subcutaneous tissue disorders1/101/10
Sore throatInfections and infestations1/100/10
Herpes LabialisInfections and infestations0/101/10
Nasal CongestionInfections and infestations1/100/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Prurigo NodularisChronic Pruritus of Unknown OriginTotal
Mean58.6 ± 13.170.7 ± 5.664.7 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Prurigo NodularisChronic Pruritus of Unknown OriginTotal
Female10212
Male088
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prurigo NodularisChronic Pruritus of Unknown OriginTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American505
White51015
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Prurigo NodularisChronic Pruritus of Unknown OriginTotal
United States101020
08

Study locations

1 site
  • Johns Hopkins Outpatient Center
    Baltimore, Maryland 21205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jul 2022, 10 months.

Results were first posted in Jul 2023, 11 months after primary completion.

Of 52 phase 2 interventional studies under Pruritus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 31. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2021
First posted
Sep 9, 2021
StartActual
Sep 9, 2021
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Results first posted
Jul 3, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05038982
Collaborators
Duke University, Pfizer
Responsible party
Sponsor
First posted
Sep 9, 2021
Start date
Sep 9, 2021
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Results posted
Jul 3, 2023
Last update
Jul 3, 2023

Study contacts

Shawn G Kwatra, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion